Cellectis Presents Updated Clinical and Translational Data
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
Source: globenewswire.com
Stay updated with breaking news from Intermediate Dose Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
NEW YORK, June 09, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated... | June 9, 2023
FinancialContent fully hosted finance channel